# Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

> **NCT01752881** · PHASE4 · COMPLETED · sponsor: **Adimmune Corporation** · enrollment: 130 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza vaccine (split virion, inactivated)
- **BIOLOGICAL:** AdimFlu-S

## Key facts

- **NCT ID:** NCT01752881
- **Lead sponsor:** Adimmune Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2012-08
- **Final completion:** 2012-09
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2012-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01752881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01752881, "Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01752881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*